← FDA DRUG APPROVALS

FDA ANDA · ANDA062252

OXACILLIN SODIUM

Sponsor: TEVA

APPLICATION
ANDA062252
TYPE
ANDA
ORIGINAL APPROVAL
1980-05-15
LATEST ACTION
2000-07-07
ROUTE
ORAL
DOSAGE FORM
FOR SOLUTION
MARKETING STATUS
Discontinued

Products

OXACILLIN SODIUMDiscontinued
OXACILLIN SODIUM EQ 250MG BASE/5ML · FOR SOLUTION · ORAL

Approval history

2000-07-07Manufacturing (CMC) · Supplement 5AP
1997-12-22Manufacturing (CMC) · Supplement 4AP
1997-08-19Manufacturing (CMC) · Supplement 3AP
1996-08-30Manufacturing (CMC) · Supplement 2AP
1994-12-22Manufacturing (CMC) · Supplement 1AP
1980-05-15OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →